

Stefan Michiels

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5728225/stefan-michiels-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260
papers

18,298
citations

63
h-index

132
g-index

339
ext. papers

22,566
ext. citations

6.3
avg, IF

6.22
L-index

#	Paper	IF	Citations
260	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.. <i>Npj Breast Cancer</i> , 2022 , 8, 3	7.8	4
259	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101252	2.2	5
258	Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer Survivors.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 1-13	7.3	0
257	A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design.. <i>Trials</i> , 2022 , 23, 193	2.8	1
256	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101958	2.2	2
255	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101536	2.2	2
254	Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France.. <i>JAMA Network Open</i> , 2022 , 5, e225118	10.4	0
253	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2100277	2.2	1
252	Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer.. <i>BMC Cancer</i> , 2022 , 22, 526	4.8	0
251	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021 , 7, 150	7.8	17
250	Validation of a new fully automated software for 2D digital mammographic breast density evaluation in predicting breast cancer risk. <i>Scientific Reports</i> , 2021 , 11, 19884	4.9	1
249	Penalized Poisson model for network meta-analysis of individual patient time-to-event data. <i>Statistics in Medicine</i> , 2021 , 41, 340	2.3	1
248	A frequentist one-step model for a simple network meta-analysis of time-to-event data in presence of an effect modifier. <i>PLoS ONE</i> , 2021 , 16, e0259121	3.7	0
247	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 1653-1665	4.4	2
246	Biomarker Discovery and Validation: Statistical Considerations. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 537-545	8.9	9
245	Assessing the risk of severe post-treatment (tx) cancer-related fatigue (CRF) among breast cancer survivors (BCS) in the CANCER TOXicity (CANTO) cohort.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 12022-12022	2.2	2
244	Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4067-4067	2.2	0

243	Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions. <i>Annals of Surgical Oncology</i> , 2021 , 28, 2138-2145	3.1	1
242	Prognostic and predictive effect of gene copy number and mutation status in early stage non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2021 , 10, 826-838	4.4	1
241	Impact of COVID-19 on healthcare organisation and cancer outcomes. <i>European Journal of Cancer</i> , 2021 , 153, 123-132	7.5	8
240	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. <i>Cancer Cell</i> , 2021 , 39, 1039-1041	24.3	0
239	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. <i>Cancers</i> , 2021 , 13,	6.6	2
238	Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 517-529	4.4	1
237	The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. <i>Annals of Oncology</i> , 2021 , 32, 1236-1244	10.3	21
236	Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. <i>European Journal of Cancer</i> , 2021 , 157, 278-290	7.5	2
235	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020 , 11, 6335	17.4	15
234	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020 , 6, 15	7.8	8
233	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020 , 132, 211-223	7.5	23
232	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020 , 6, 16	7.8	47
231	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 17	7.8	54
230	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2762-2772	2.2	39
229	Integrating expert's knowledge constraint of time dependent exposures in structure learning for Bayesian networks. <i>Artificial Intelligence in Medicine</i> , 2020 , 107, 101874	7.4	3
228	A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. <i>ERJ Open Research</i> , 2020 , 6,	3.5	1
227	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100023	1.4	4
226	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020 , 250, 667-684	9.4	83

225	Accounting for grouped predictor variables or pathways in high-dimensional penalized Cox regression models. <i>BMC Bioinformatics</i> , 2020 , 21, 277	3.6	2
224	Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. <i>Breast</i> , 2020 , 52, 23-32	3.6	8
223	Development and Validation of Risk Prediction Models 2020 , 1-22		1
222	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21080-e21080	2.2	
221	On the Use of Neural Networks with Censored Time-to-Event Data. <i>Lecture Notes in Computer Science</i> , 2020 , 56-67	0.9	1
220	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 242-255	12.9	55
219	Quality-of-life assessment in French patients with metastatic melanoma in real life. <i>Cancer</i> , 2020 , 126, 611-618	6.4	4
218	Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. <i>International Journal of Cancer</i> , 2020 , 147, 266-276	7.5	6
217	Meta-analysis of clinical trials with competing time-to-event endpoints. <i>Biometrical Journal</i> , 2020 , 62, 712-723	1.5	1
216	Prediction of Breast Cancer Treatment-Induced Fatigue by Machine Learning Using Genome-Wide Association Data. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa039	4.6	1
215	Predictive classifier for intensive treatment of head and neck cancer. <i>Cancer</i> , 2020 , 126, 5263-5273	6.4	3
214	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020 , 31, 1491-1505	10.3	223
213	Body weight and return to work among survivors of early-stage breast cancer. <i>ESMO Open</i> , 2020 , 5, e000908	6.0	6
212	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020 , 4, 27	9.8	3
211	Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 387-401	4.4	5
210	Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study. <i>Statistical Methods in Medical Research</i> , 2020 , 29, 1483-1498	2.3	2
209	An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error. <i>Contemporary Clinical Trials Communications</i> , 2019 , 15, 100402	1.8	1
208	Fatigue and physical activity in cancer survivors: A cross-sectional population-based study. <i>Cancer Medicine</i> , 2019 , 8, 2535-2544	4.8	13

207	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019 , 37, 559-569	2.2	282
206	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1169-1178	2.2	127
205	EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019 , 117, 60-68	7.5	43
204	Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy. <i>Annals of Oncology</i> , 2019 , 30, v55	10.3	3
203	Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. <i>Annals of Oncology</i> , 2019 , 30, 1784-1795	10.3	57
202	Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 10018-10018	2.2	2
201	Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 512-512	2.2	1
200	Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. <i>Annals of Oncology</i> , 2019 , 30, 1941-1949	10.3	78
199	Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2019 , 30, 236-242	10.3	70
198	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 134, 39-45	7	129
197	A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. <i>Statistical Methods in Medical Research</i> , 2019 , 28, 170-183	2.3	11
196	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 560-567	9.7	137
195	Multivariate joint frailty model for the analysis of nonlinear tumor kinetics and dynamic predictions of death. <i>Statistics in Medicine</i> , 2018 , 37, 2148-2161	2.3	4
194	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. <i>European Journal of Cancer</i> , 2018 , 92, 1-10	7.5	11
193	surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials. <i>Computer Methods and Programs in Biomedicine</i> , 2018 , 155, 189-198	6.9	23
192	A benchmark study of scoring methods for non-coding mutations. <i>Bioinformatics</i> , 2018 , 34, 1635-1641	7.2	13
191	biospear: an R package for biomarker selection in penalized Cox regression. <i>Bioinformatics</i> , 2018 , 34, 112-113	7.2	9
190	The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. <i>Annals of Oncology</i> , 2018 , 29, 30-35	10.3	57

189	ER Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. <i>Clinical Cancer Research</i> , 2018 , 24, 2517-2529	12.9	19
188	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. <i>Annals of Oncology</i> , 2018 , 29, 162-169	10.3	26
187	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018 , 52, 16-25	12.7	181
186	Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting. <i>BMC Medical Research Methodology</i> , 2018 , 18, 67	4.7	0
185	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. <i>Seminars in Cancer Biology</i> , 2018 , 52, 151-157	12.7	71
184	All simulation models of breast cancer are wrong but some are useful. <i>The Lancet Global Health</i> , 2018 , 6, e818-e819	13.6	
183	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2018 , 24, 153-162	2.2	11
182	Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. <i>Annals of Oncology</i> , 2018 , 29, 1755-1762	10.3	23
181	Abstract CT101: D-BEYOND: A window of opportunity trial evaluating denosumab, a RANKL inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer 2018 ,		4
180	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of indolent Stage IV disease (Stage IV indolent).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1019-1019	2.2	3
179	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018 , 9, 9741-9750	3.3	7
178	Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 571-571	2.2	
177	Steps forward for cancer precision medicine. <i>Nature Reviews Drug Discovery</i> , 2018 , 17, 1-2	64.1	27
176	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology</i> , 2018 , 19, 27-39	11.7	413
175	Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study. <i>Oncotarget</i> , 2018 , 9, 1906-1914	3.3	10
174	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2995-3006	2.2	120
173	Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2018 , 36, 981-990	2.2	61
172	Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort. <i>Annals of Oncology</i> , 2018 , 29, viii704	10.3	3

171	Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays. <i>PLoS ONE</i> , 2018 , 13, e0203346	3.7	2
170	Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. <i>European Journal of Cancer</i> , 2018 , 105, 33-40	7.5	25
169	Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?. <i>European Journal of Cancer</i> , 2018 , 103, 108-119	7.5	12
168	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018 , 7, 416-427	4.4	6
167	Robotic Prophylactic Nipple-Sparing Mastectomy with Immediate Prosthetic Breast Reconstruction: A Prospective Study. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2579-2586	3.1	50
166	Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology. <i>Computational and Mathematical Methods in Medicine</i> , 2018 , 2018, 1672176	2.8	5
165	A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups. <i>Annals of Oncology</i> , 2017 , 28, 1523-1531	10.3	58
164	Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events. <i>Journal of Biopharmaceutical Statistics</i> , 2017 , 27, 1043-1053	1.3	1
163	Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region. <i>Public Health</i> , 2017 , 149, 81-88	4	4
162	Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors". <i>Drugs</i> , 2017 , 77, 1139-1140	12.1	0
161	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. <i>Cancer Discovery</i> , 2017 , 7, 586-595	24.4	347
160	Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. <i>Drugs</i> , 2017 , 77, 713-719	12.1	22
159	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology</i> , 2017 , 18, 52-62	21.7	164
158	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	31
157	Evaluating Personalized Medicine in Multi-marker Multi-treatment Clinical Trials: Accounting for Heterogeneity 2017 , 125-149		
156	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). <i>European Journal of Cancer</i> , 2017 , 85, 133-145	7.5	54
155	Predictors of responses to immune checkpoint blockade in advanced melanoma. <i>Nature Communications</i> , 2017 , 8, 592	17.4	122
154	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 6101-6112	12.9	58

153	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Metastatic Tumors. <i>Early Clinical and Oncology Biomarkers</i> , 2017 , 1, 1-10	5.1	299
152	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Precision Oncology</i> , 2017 , 1, 1-10	5.1	293
151	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. <i>European Journal of Cancer</i> , 2017 , 87, 122-130	7.5	75
150	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017 , 377, 1836-1846	59.2	610
149	Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials. <i>BMC Medical Research Methodology</i> , 2017 , 17, 83	4.7	5
148	Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces. <i>Biometrical Journal</i> , 2017 , 59, 685-701	1.5	17
147	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2017 , 28, v68	10.3	3
146	Abstract CT004: European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study 2017 ,		8
145	Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy 2017 ,		5
144	Fatigue and health behaviors in cancer survivors: A cross-sectional population based study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10069-10069	2.2	1
143	Tutorial in Joint Modeling and Prediction: A Statistical Software for Correlated Longitudinal Outcomes, Recurrent Events and a Terminal Event. <i>Journal of Statistical Software</i> , 2017 , 81,	7.3	21
142	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 575-575	2.2	1
141	Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. <i>Annals of Oncology</i> , 2016 , 27, 2160-2167	10.3	21
140	Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. <i>BMC Medical Research Methodology</i> , 2016 , 16, 37	4.7	20
139	New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study. <i>Statistics in Medicine</i> , 2016 , 35, 3245-58	2.3	6
138	Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. <i>Cancer Research</i> , 2016 , 76, 264-74	10.1	17
137	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. <i>JAMA Oncology</i> , 2016 , 2, 217-24	13.4	19
136	Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2016 , 27, 1029-1034	10.3	27

135	Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma. <i>American Journal of Pathology</i> , 2016 , 186, 435-45	5.8	14
134	Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial 2016 ,		10
133	Abstract P1-14-01: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive,PIK3CAmutant andPIK3CAwild-type primary breast cancer [NeopHOEBE 2016 ,		4
132	Abstract S1-03: Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy 2016 ,		18
131	Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. <i>PLoS ONE</i> , 2016 , 11, e0154009	3.7	21
130	Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data. <i>Oncotarget</i> , 2016 , 7, 3002-17	3.3	11
129	Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial. <i>Biometrics</i> , 2016 , 72, 907-16	1.8	21
128	Empirical extensions of the lasso penalty to reduce the false discovery rate in high-dimensional Cox regression models. <i>Statistics in Medicine</i> , 2016 , 35, 2561-73	2.3	52
127	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016 , 29, 1155-64	9.8	154
126	The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. <i>Science Translational Medicine</i> , 2016 , 8, 369ra177	17.5	14
125	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. <i>JAMA Oncology</i> , 2016 , 2, 1040-7	13.4	48
124	Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients. <i>Molecular Oncology</i> , 2016 , 10, 1430-1436	7.9	5
123	Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. <i>Annals of Oncology</i> , 2016 , 27, 1860-6	10.3	40
122	Precision medicine for metastatic breast cancer--limitations and solutions. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 693-704	19.4	201
121	A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 415-26	4.4	5
120	MÉa-analyses d'essais randomis sur donnes individuelles dans le traitement des cancers ORL non mtastatiques : principes, rsultats, perspectives. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015 , 19, 233	1.3	
119	MÉa-analyses d'essais randomis sur donnes individuelles dans le traitement des cancers ORL non mtastatiques : principes, rsultats, perspectives. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015 , 19, 228-229	1.3	
118	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. <i>JAMA Oncology</i> , 2015 , 1, 448-54	13.4	359

117	Mining the coding and non-coding genome for cancer drivers. <i>Cancer Letters</i> , 2015 , 369, 307-15	9.9	9
116	Reply to V.P. Retellet al, D. Gauchan et al, and C. Rahilly-Tierney et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1629-30	2.2	
115	Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 680-6	2	6
114	467 Radiomics to identify HER2 amplification or mutation in metastatic patients with solid tumors prospectively enrolled in MOSCATO-01. <i>European Journal of Cancer</i> , 2015 , 51, S101	7.5	2
113	3133 Prognostic value of texture analysis and correlation with molecular profile in EGFR mutated/ALK rearranged advanced non-small cell lung cancer (NSCLC). <i>European Journal of Cancer</i> , 2015 , 51, S647-S648	7.5	6
112	3127 Prognostic value of texture analysis in advanced non-small cell lung cancer (NSCLC). <i>European Journal of Cancer</i> , 2015 , 51, S645-S646	7.5	4
111	Prediction of treatment benefit in high-dimensional cox models via gene signatures in randomized clinical trials. <i>Trials</i> , 2015 , 16,	2.8	78
110	A Dual Model for Prioritizing Cancer Mutations in the Non-coding Genome Based on Germline and Somatic Events. <i>PLoS Computational Biology</i> , 2015 , 11, e1004583	5	14
109	Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) <i>Annals of Oncology</i> , 2015 , 26, 873-879	10.3	89
108	A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer. <i>Statistical Methods in Medical Research</i> , 2015 , 24, 711-29	2.3	28
107	Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. <i>Public Health Genomics</i> , 2015 , 18, 349-58	1.9	11
106	Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 516-516	2.2	5
105	Predictive ability of tumor growth modeling for overall survival in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14619-e14619	2.2	
104	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. <i>Lancet, The</i> , 2014 , 383, 2127-35	4.0	1237
103	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology, The</i> , 2014 , 15, 406-14	21.7	566
102	Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3513-9	2.2	23
101	Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. <i>Annals of Oncology</i> , 2014 , 25, 1959-1965	10.3	181
100	Testing the treatment effect on competing causes of death in oncology clinical trials. <i>BMC Medical Research Methodology</i> , 2014 , 14, 72	4.7	5

99	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. <i>Annals of Oncology</i> , 2014 , 25, 1544-50	10.3	780
98	Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. <i>BMC Genomics</i> , 2014 , 15, 1008	4.5	45
97	Statistical methods applied to omics data: predicting response to neoadjuvant therapy in breast cancer. <i>Current Opinion in Oncology</i> , 2014 , 26, 576-83	4.2	3
96	International study on inter-reader variability for circulating tumor cells in breast cancer. <i>Breast Cancer Research</i> , 2014 , 16, R43	8.3	41
95	Incidence and mortality rates of breast and gynecologic cancers and human development index in the pan-American region.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1596-1596	2.2	2
94	Nonmetastatic inflammatory breast cancer: Evolution of invasive disease-free (IDFS) and overall survival (OS) over a 21-year period.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1082-1082	2.2	
93	Evaluation of PI3K-pathway activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11060-11060	2.2	
92	Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients. <i>Genomics Data</i> , 2013 , 1, 7-10		3
91	A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. <i>Molecular Oncology</i> , 2013 , 7, 987-99	7.9	29
90	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. <i>Journal of Clinical Oncology</i> , 2013 , 31, 860-7	2.2	1023
89	Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1667-70	9.7	58
88	Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013 , 49, 1565-77	7.5	119
87	Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. <i>Lancet Oncology</i> , 2013 , 14, 619-26	21.7	141
86	Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1600-7	9.7	102
85	Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. <i>European Journal of Cancer</i> , 2013 , 49, 1882-8	7.5	2
84	Genomic grade adds prognostic value in invasive lobular carcinoma. <i>Annals of Oncology</i> , 2013 , 24, 377-384	6.3	35
83	Omics-based clinical trial designs. <i>Current Opinion in Oncology</i> , 2013 , 25, 289-95	4.2	13
82	Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. <i>Annals of Oncology</i> , 2013 , 24, 647-54	10.3	96

81	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 960-7	9.7	112
80	Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis. <i>PLoS ONE</i> , 2013 , 8, e62451	3.7	23
79	Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer. <i>PLoS ONE</i> , 2013 , 8, e66848	3.7	13
78	Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer [NeoPHOEBE 2013 ,		2
77	Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC) 2013 ,		15
76	CD4+ follicular helper T cell infiltration predicts breast cancer survival. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2873-92	15.9	554
75	Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 610-610	2.2	1
74	PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. <i>PLoS ONE</i> , 2013 , 8, e53292	3.7	64
73	Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1490-502	8.9	65
72	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <i>Lancet Oncology</i> , 2012 , 13, e240-8	21.7	51
71	Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. <i>European Respiratory Journal</i> , 2012 , 39, 172-9	13.6	31
70	Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012 , 461, 441-8	5.1	42
69	Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. <i>Annals of Oncology</i> , 2012 , 23, 2059-2064	10.3	11
68	Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. <i>Clinical Cancer Research</i> , 2012 , 18, 1341-51	12.9	239
67	Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. <i>Clinical Cancer Research</i> , 2012 , 18, 1004-14	12.9	39
66	Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1996-2004	2.2	167
65	Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. <i>Annals of Oncology</i> , 2012 , 23, 2997-3006	10.3	189
64	Biomarker studies: a call for a comprehensive biomarker study registry. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 171-6	19.4	86

63	Multidimensionality of microarrays: statistical challenges and (im)possible solutions. <i>Molecular Oncology</i> , 2011 , 5, 190-6	7.9	19
62	Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1. <i>Human Pathology</i> , 2011 , 42, 1727-39	3.7	19
61	HER2-positive circulating tumor cells in breast cancer. <i>PLoS ONE</i> , 2011 , 6, e15624	3.7	156
60	Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project—part 1). <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1006-15	8.9	43
59	Time to move forward from "first-generation" prognostic gene signatures in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 643-5	4.4	1
58	Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint. <i>Statistics in Medicine</i> , 2011 , 30, 1502-18	2.3	8
57	DNA methylation profiling reveals a predominant immune component in breast cancers. <i>EMBO Molecular Medicine</i> , 2011 , 3, 726-41	12	167
56	Integrating biomarkers in clinical trials. <i>Expert Review of Molecular Diagnostics</i> , 2011 , 11, 171-82	3.8	104
55	Proteomic changes associated with breast cancer progression in the MCF10AT model. <i>Pharmacogenomics</i> , 2011 , 12, 9-10	2.6	1
54	Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. <i>Haematologica</i> , 2011 , 96, 1106-12	6.6	31
53	Multifactorial approach to predicting resistance to anthracyclines. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1578-86	2.2	143
52	Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. <i>Endocrine-Related Cancer</i> , 2011 , 18, 721-30	5.7	6
51	Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib. <i>Blood</i> , 2011 , 118, 1877-1877	2.2	3
50	Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (A). <i>Journal of Clinical Oncology</i> , 2011 , 29, 551-551	2.2	3
49	Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 7004-7004	2.2	3
48	S1-6: Characterization of Breast Cancer Distant Metastasis Based on Outcome over Time Using a Gene Expression Profiling Approach and Identification of Pathway Activities of Late Relapse. 2011 ,		3
47	Clinical usefulness of microarrays for cancer prognosis in 2010--letter. <i>Clinical Cancer Research</i> , 2010 , 16, 6180; author reply 6181	12.9	1
46	Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 1729-37	27.4	586

45	CXCR4 expression in early breast cancer and risk of distant recurrence. <i>Oncologist</i> , 2009 , 14, 1182-8	5.7	52
44	Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. <i>Clinical Cancer Research</i> , 2009 , 15, 441-51	12.9	265
43	Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5965-71	2.2	19
42	Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. <i>Cancer Research</i> , 2009 , 69, 3563-9	10.1	160
41	Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk. <i>Carcinogenesis</i> , 2009 , 30, 763-8	4.6	34
40	Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. <i>Lancet Oncology, The</i> , 2009 , 10, 341-50	21.7	118
39	Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. <i>Lancet Oncology, The</i> , 2009 , 10, 381-90	21.7	50
38	Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. <i>Molecular Oncology</i> , 2008 , 1, 425-30	7.9	41
37	Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. <i>Annals of Oncology</i> , 2008 , 19, 315-20	10.3	28
36	Individual- and trial-level surrogacy in colorectal cancer. <i>Statistical Methods in Medical Research</i> , 2008 , 17, 467-75	2.3	48
35	Investigating trial and treatment heterogeneity in an individual patient data meta-analysis of survival data by means of the penalized maximum likelihood approach. <i>Statistics in Medicine</i> , 2008 , 27, 1894-910	2.3	31
34	Variants in DNA double-strand break repair and DNA damage-response genes and susceptibility to lung and head and neck cancers. <i>International Journal of Cancer</i> , 2008 , 123, 457-463	7.5	18
33	Expression of erythropoietin and its receptor in neuroblastomas. <i>Cancer</i> , 2007 , 110, 1096-106	6.4	23
32	Interpretation of microarray data in cancer. <i>British Journal of Cancer</i> , 2007 , 96, 1155-8	8.7	73
31	Progression-free survival is a surrogate for survival in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5218-24	2.2	278
30	Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. <i>Annals of Oncology</i> , 2007 , 18, 1043-50	10.3	48
29	Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. <i>Annals of Oncology</i> , 2007 , 18, 1477-83	10.3	66
28	Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. <i>Annals of Oncology</i> , 2007 , 18, 1285-6	10.3	63

27	Sodium/iodide symporter (NIS) gene expression is the limiting step for the onset of thyroid function in the human fetus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 70-6	5.6	65
26	Five-gene signature in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2007 , 356, 1581-2; author reply 1583	59.2	2
25	Polymorphism discovery in 62 DNA repair genes and haplotype associations with risks for lung and head and neck cancers. <i>Carcinogenesis</i> , 2007 , 28, 1731-9	4.6	60
24	Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. <i>Cochrane Database of Systematic Reviews</i> , 2007 , CD004569		26
23	Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis?. <i>European Journal of Cancer</i> , 2007 , 43, 745-51	7.5	82
22	Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2007 , 8, 994-1000	21.7	86
21	Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4512-4512	2.2	37
20	Cxcr4 expression and risk of bone metastasis in patients with early breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 10610-10610	2.2	
19	Gene expression profiling of primary cutaneous melanoma and clinical outcome. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 472-82	9.7	410
18	Application of an acceptance sampling plan for post-production quality control of chemotherapeutic batches in a hospital pharmacy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2006 , 64, 92-8	5.7	14
17	HEX, PAX-8 and TTF-1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism. <i>Clinical Endocrinology</i> , 2006 , 64, 398-404	3.4	12
16	Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma. <i>Modern Pathology</i> , 2006 , 19, 1170-80	9.8	19
15	In reply to Drs. Huncharek and Kupelnick. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 65, 958-959	4	4
14	Prediction of cancer outcome with microarrays: a multiple random validation strategy. <i>Lancet, The</i> , 2005 , 365, 488-92	40	815
13	Prediction of cancer outcome with microarrays. <i>Lancet, The</i> , 2005 , 365, 1683; author reply 1684-5	40	12
12	Prediction of cancer outcome with microarrays. <i>Lancet, The</i> , 2005 , 365, 1684-1685	40	8
11	False discovery rate, sensitivity and sample size for microarray studies. <i>Bioinformatics</i> , 2005 , 21, 3017-247.2		340
10	Random effects survival models gave a better understanding of heterogeneity in individual patient data meta-analyses. <i>Journal of Clinical Epidemiology</i> , 2005 , 58, 238-45	5.7	25

9	Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. <i>American Journal of Pathology</i> , 2005 , 167, 223-31	5.8	69
8	Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. <i>Annals of Oncology</i> , 2005 , 16, 1906-14	10.3	52
7	Validation of microarray data by quantitative reverse-transcriptase polymerase chain reaction. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9439-40; author reply 9440	2.2	5
6	Bias in the estimation of false discovery rate in microarray studies. <i>Bioinformatics</i> , 2005 , 21, 3865-72	7.2	63
5	Meta-analysis when only the median survival times are known: a comparison with individual patient data results. <i>International Journal of Technology Assessment in Health Care</i> , 2005 , 21, 119-25	1.8	106
4	Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3766-75	2.2	295
3	Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 470-84	27.4	260
2	Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. <i>Cancer</i> , 2004 , 100, 28-35	6.4	71
1	Textbook of Clinical Trials in Oncology		3